{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:21:31Z","timestamp":1780608091340,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T00:00:00Z","timestamp":1537574400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00345-018-2495-0","type":"journal-article","created":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T12:44:27Z","timestamp":1537620267000},"page":"1085-1093","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["New study suggests patients with advanced prostate cancer on androgen deprivation therapy need more dialogue with health care provider, especially around cardiovascular risk"],"prefix":"10.1007","volume":"37","author":[{"given":"Axel","family":"Merseburger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bro Falkenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga J.","family":"Kornilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,22]]},"reference":[{"key":"2495_CR1","unstructured":"Prostate cancer statistics [Internet]: Centers for Disease Control and Prevention, CDC (US). Updated on 23 May 2017. https:\/\/www.cdc.gov\/cancer\/prostate\/statistics\/index.htm . Accessed 19 Jan 2018"},{"key":"2495_CR2","unstructured":"Key statistics for Prostate cancer [Internet]. American Cancer Society. https:\/\/www.cancer.org\/cancer\/prostate-cancer\/about\/key-statistics.html . Accessed 19 Jan 2018"},{"key":"2495_CR3","first-page":"805","volume":"19","author":"ZQ Tao","year":"2015","unstructured":"Tao ZQ, Shi AM, Wang KX, Zhang WD (2015) Epidemiology of prostate cancer: current status. Eur Rev Med Pharmacol Sci 19:805\u2013812","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2495_CR4","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.juro.2016.12.086","volume":"197","author":"AZ Fu","year":"2017","unstructured":"Fu AZ, Tsai H-T, Haque R, Yood MU, Cassidy-Bushrow AE, Van Den Eeden SK, Keating NL, Smith MR, Zhou Y, Aaronson DS, Potosky AL (2017) Mortality and androgen deprivation therapy as salvage treatment for biochemical recurrence after primary therapy for clinically localized prostate cancer. J Urol 197:1448\u20131454","journal-title":"J Urol"},{"key":"2495_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11934-017-0688-5","volume":"18","author":"AK Greiman","year":"2017","unstructured":"Greiman AK, Keane TE (2017) Approach to androgen deprivation in the prostate cancer patient with pre-existing cardiovascular disease. Curr Urol Rep 18:41","journal-title":"Curr Urol Rep"},{"key":"2495_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/djp404","volume":"102","author":"NL Keating","year":"2010","unstructured":"Keating NL, O\u2019Malley AJ, Freedland SJ, Smith MR (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102:39\u201346","journal-title":"J Natl Cancer Inst"},{"key":"2495_CR7","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/cncr.22933","volume":"110","author":"CS Saigal","year":"2007","unstructured":"Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS, Urologic Diseases in America Project (2007) Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110:1493\u20131500","journal-title":"Cancer"},{"key":"2495_CR8","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","volume":"121","author":"G Levine","year":"2010","unstructured":"Levine G, D\u2019Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N (2010) Androgen deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urologic Association: endorsed by the American Society for Radiation Oncology. Circulation 121:833\u2013840","journal-title":"Circulation"},{"key":"2495_CR9","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1093\/jnci\/djm168","volume":"99","author":"HK Tsai","year":"2007","unstructured":"Tsai HK, D\u2019Amico AV, Sadetsky N, Chen MH, Carroll PR (2007) Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99:1516\u20131524","journal-title":"J Natl Cancer Inst"},{"key":"2495_CR10","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/bjc.2017.280","volume":"117","author":"R Haque","year":"2017","unstructured":"Haque R, UlcickasYood M, Xu X, Cassidy-Bushrow AE, Tsai HT, Keating NL, Van Den Eeden SK, Potosky AL (2017) Cardiovascular disease risk and androgen deprivation therapy in patients with localized prostate cancer: a prospective cohort study. Br J Cancer 117:1233\u20131240","journal-title":"Br J Cancer"},{"key":"2495_CR11","doi-asserted-by":"publisher","first-page":"820403","DOI":"10.1155\/2015\/820403","volume":"2015","author":"MK Davis","year":"2015","unstructured":"Davis MK, Rajala JL, Tyldesley S, Pickles T, Virani SA (2015) The prevalence of cardiac risk factors in men with localized prostate cancer undergoing androgen deprivation therapy in British Columbia, Canada. J Oncol 2015:820403. https:\/\/doi.org\/10.1155\/2015\/820403","journal-title":"J Oncol"},{"key":"2495_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.eururo.2012.04.035","volume":"64","author":"NL Keating","year":"2013","unstructured":"Keating NL, O\u2019Malley AJ, Freedland SJ, Smith MR (2013) Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol 64:159\u2013166","journal-title":"Eur Urol"},{"issue":"55\u201358","key":"2495_CR13","first-page":"65","volume":"29","author":"ED Crawford","year":"2015","unstructured":"Crawford ED, Moul JW (2015) ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury. Oncology 29(55\u201358):65\u201366","journal-title":"Oncology"},{"key":"2495_CR14","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.clgc.2014.12.003","volume":"13","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia G, Sun M, Popa I, Schiffmann J, Trudeau V, Shariat SF, Trinh QD, Graefen M, Widmer H, Saad F, Briganti A, Montorsi F, Karakiewicz PI (2015) Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: a population-based study. Clin Genitourin Cancer 13:e123\u2013e130","journal-title":"Clin Genitourin Cancer"},{"key":"2495_CR15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.urology.2007.01.027","volume":"69","author":"SL Snow","year":"2007","unstructured":"Snow SL, Panton RL, Butler LJ, Wilke DR, Rutledge RDH, Bell DG, Rendon RA (2007) Incomplete and inconsistent information provided to men making decisions for treatment of early-stage prostate cancer. Urology 69:941\u2013945","journal-title":"Urology"},{"key":"2495_CR16","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1002\/cncr.23807","volume":"113","author":"BD Sommers","year":"2008","unstructured":"Sommers BD, Beard CJ, D\u2019Amico AV, Kaplan I, Richie JP, Zeckhauser RJ (2008) Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 113:2058\u20132067","journal-title":"Cancer"},{"key":"2495_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1464-410X.2011.10709.x","volume":"110","author":"PL Nguyen","year":"2012","unstructured":"Nguyen PL, Chen MH, Hoffman KE, Chen RC, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, D\u2019Amico AV (2012) Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int 110:201\u2013205","journal-title":"BJU Int"},{"key":"2495_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pec.2012.12.002","volume":"91","author":"L Song","year":"2013","unstructured":"Song L, Bensen JT, Zimmer C, Sleath B, Blackard B, Fontham E, Su LJ, Brennan CS, Mohler JL, Mishel M (2013) Patient-health care provider communication among patients with newly diagnosed prostate cancer: findings from a population-based survey. Patient Educ Couns 91:79\u201384","journal-title":"Patient Educ Couns"},{"key":"2495_CR19","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018"},{"key":"2495_CR20","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1200\/JCO.2010.29.1567","volume":"28","author":"M Hemelrijck Van","year":"2010","unstructured":"Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, Lambe M, Stattin P, Adolfsson J (2010) Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol 28:3448\u20133456","journal-title":"J Clin Oncol"},{"key":"2495_CR21","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","volume":"121","author":"GN Levine","year":"2010","unstructured":"Levine GN, D\u2019Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky Zakai SN (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk. Circulation 121:833\u2013840","journal-title":"Circulation"},{"key":"2495_CR22","doi-asserted-by":"crossref","first-page":"493","DOI":"10.4103\/1008-682X.143313","volume":"17","author":"JY Teoh","year":"2015","unstructured":"Teoh JY, Chan SY, Chiu PK, Poon DM, Cheung HY, Hou SS, Ng CF (2015) Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer. Asian J Androl 17:493\u2013496","journal-title":"Asian J Androl"},{"key":"2495_CR23","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1200\/JCO.2016.71.4204","volume":"35","author":"DY Chen","year":"2017","unstructured":"Chen DY, See LC, Liu JR, Chuang CK, Pang ST, Hsieh IC, Wen MS, Chen TH, Lin YC, Liaw CC, Hsu CL, Chang JW, Kuo CF, Huang WK (2017) Risk of cardiovascular ischemic events after surgical castration and gonadotropin-releasing hormone agonist therapy for prostate cancer: a nationwide cohort study. J Clin Oncol 35:3697\u20133705","journal-title":"J Clin Oncol"},{"key":"2495_CR24","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","volume":"33","author":"S O\u2019Farrell","year":"2015","unstructured":"O\u2019Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M (2015) Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 33:1243\u20131251","journal-title":"J Clin Oncol"},{"key":"2495_CR25","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","volume":"16","author":"R Iacovelli","year":"2018","unstructured":"Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D, Muraglia A, Porcaro AB, Siracusano S, Brunelli M, Mazzarotto R, Artibani W, Tortora G (2018) The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer. Clin Genitourin Cancer 16:e645\u2013e653","journal-title":"Clin Genitourin Cancer"},{"key":"2495_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.canrad.2016.02.015","volume":"20","author":"I Latorzeff","year":"2016","unstructured":"Latorzeff I, Ploussard G, Guillotreau J, Jonca F, Labarthe P, Rollin G, Beauval JB, Pathak A (2016) Cardiovascular risks with prostate cancer hormonal treatment: rationale for a department of oncocardiology. Cancer Radiother 20:405\u2013410","journal-title":"Cancer Radiother"},{"key":"2495_CR27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","volume":"133","author":"N Bhatia","year":"2016","unstructured":"Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, Moslehi J (2016) Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation 133:537\u2013541","journal-title":"Circulation"},{"key":"2495_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/PPO.0b013e31819764cc","volume":"15","author":"SJ Knight","year":"2009","unstructured":"Knight SJ, Latini DM (2009) Sexual side effects and prostate cancer treatment decisions: patient information needs and preferences. Cancer J 15:41\u201344","journal-title":"Cancer J"},{"key":"2495_CR29","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1111\/bju.13122","volume":"117","author":"E Watson","year":"2016","unstructured":"Watson E, Shinkins B, Frith E, Neal D, Hamdy F, Walter F, Weller D, Wilkinson C, Faithfull S, Wolstenholme J, Sooriakumaran P, Kastner C, Campbell C, Neal R, Butcher H, Matthews M, Perera R, Rose P (2016) Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up. BJU Int 117:E10\u2013E19","journal-title":"BJU Int"},{"key":"2495_CR30","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1038\/sj.pcan.4500623","volume":"5","author":"RO Fourcade","year":"2002","unstructured":"Fourcade RO, Mensink P, Ernemo B, Ligensa C (2002) The value of patient\u2013doctor dialog in the treatment of early prostate cancer. Prostate Cancer Prostatic Dis 5:S12\u2013S14","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2495_CR31","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1185\/030079907X223800","volume":"23","author":"C Hardy","year":"2007","unstructured":"Hardy C, Penn S, Morris T (2007) Attitudes of prostate cancer patients towards the diagnosis and treatment of their disease: findings from a multinational survey. Curr Med Res Opin 23:2107\u20132116","journal-title":"Curr Med Res Opin"},{"key":"2495_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/aja.2011.105","volume":"14","author":"S Basaria","year":"2012","unstructured":"Basaria S (2012) Time to raise awareness regarding complications of androgen deprivation therapy. Asian J Androl 14:175\u2013176","journal-title":"Asian J Androl"},{"key":"2495_CR33","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00345-004-0447-3","volume":"22","author":"M Schostak","year":"2004","unstructured":"Schostak M, Wiegel T, M\u00fcller M, Hoecht S, Schrader M, Straub B, Bottke D, Hinkelbein W, Miller K (2004) Shared decision-making\u2014results from an interdisciplinary consulting service for prostate cancer. World J Urol 22:441\u2013448","journal-title":"World J Urol"},{"key":"2495_CR34","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/01.ju.0000052056.27609.8a","volume":"169","author":"HR Patel","year":"2003","unstructured":"Patel HR, Mirsadraee S, Emberton M (2003) The patient\u2019s dilemma: prostate cancer treatment choices. J Urol 169:828\u2013833","journal-title":"J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2495-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-018-2495-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2495-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T09:31:57Z","timestamp":1693906317000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-018-2495-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,22]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["2495"],"URL":"https:\/\/doi.org\/10.1007\/s00345-018-2495-0","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,22]]},"assertion":[{"value":"26 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Axel Merseburger is the associate editor of WJU and has contributed to pharmaceutical companies like Amgen, Apogepha, Astellas, Bayer, BMS, Clovis, Ferring, Hexal, Ipsen, Janssen, Merck, MSD, Novartis, Roche, Sanofi, Takeda, TEVA. Anne Bro Falkenberg was an employee of Ferring Pharmaceuticals at the time of conduct of this survey. Olga Kornilova is an employee of Ferring Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Patients participating in this anonymous online survey were asked for their agreement. Survey was conducted according to Market research industry code of conduct and privacy rights were respected in the analysis of results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human rights"}}]}}